E. Kishino

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

J. Kurebayashi, Yoshikazu Koike, W. Saitoh, 2020, Breast Cancer.

Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells

N. Kanomata, J. Kurebayashi, Yoshikazu Koike, 2019, Breast Cancer.

Comprehensive immunohistochemical analyses on expression levels of hedgehog signaling molecules in breast cancers

N. Kanomata, J. Kurebayashi, Yoshikazu Koike, 2018, Breast Cancer.

Longitudinal Change of Postoperative Serum Anti-thyroglobulin Antibody Levels in Patients Without Total Thyroidectomy and Remnant Ablation

T. Mikami, Yoshikazu Koike, Katsuhiro Tanaka, 2021 .

Predictors for the outcomes of patients with estrogen receptor-positive, HER2-negative advanced breast cancer treated using palbociclib plus endocrine therapy

N. Kanomata, J. Kurebayashi, Yutaka Yamamoto, 2020 .